Scynexis, Inc.
A biotechnology company in Jersey City, New Jersey, that develops medicines for hard-to-treat infections and rare diseases. Its best-known product is Brexafemme, an oral pill for vaginal yeast infections that was the first new class of antifungal drug approved by the FDA in more than twenty years. The company began in 1999 as a chemistry-and-automation services firm called ScyRex, later renamed SCYNEXIS, and today also works on treatments for polycystic kidney disease.
Granted 423.8K · Bought 108.7K
Granted 129.8K
Granted 129.8K
Granted 2.9K
Granted 2.9K
Granted 2.9K
Granted 2.9K
Granted 2.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Angulo Gonzalez DavidChief Executive Officer, Director · 3 transactions | +66.2% | 1.36M | 423.8K | 108.7K | — |
| Sukenick ScottChief Legal Officer · 1 transaction | +31.6% | 574.5K | 129.8K | — | — |
| Macleod ivorChief Financial Officer · 1 transaction | +52.9% | 398.5K | 129.8K | — | — |
| Macdonald GuyDirector · 1 transaction | -83.8% | 12.6K | 2.9K | — | — |
| Tinmouth Brian PhilippeDirector · 1 transaction | -83.6% | 12.1K | 2.9K | — | — |
| Anido ArmandoDirector · 1 transaction | -83.5% | 11.8K | 2.9K | — | — |
| Hanham AnnDirector · 1 transaction | -83.4% | 11.6K | 2.9K | — | — |
| Hastings David CDirector · 1 transaction | -83.3% | 11.5K | 2.9K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last year: +108.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.